首页> Journal of neuro-oncology> Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016.

Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016.

导出原文传递

翻译打印收藏纠错

第一作者： Roberta,Rudà

第一单位： Department of Neuro-Oncology, University and City of Health and Science Hospital, Via Cherasco 15, 10126, Turin, Italy. rudarob@hotmail.com.

作者： Roberta,Rudà ^[1] ; Alessia,Pellerino ^[2] ; Andrea,Pace ^[3] ; Carmine Maria,Carapella ^[3] ; Cristina,Dealis ^[4] ; Manuela,Caroli ^[5] ; Marina,Faedi ^[6] ; Lorenzo,Bello ^[7] ; Enrica,Migliore ^[8] ; Giulia,Marchese ^[2] ; Luca,Bertero ^[9] ; Paola,Cassoni ^[9] ; Riccardo,Soffietti ^[2]

作者单位： Department of Neuro-Oncology, University and City of Health and Science Hospital, Via Cherasco 15, 10126, Turin, Italy. rudarob@hotmail.com. ^[1] Department of Neuro-Oncology, University and City of Health and Science Hospital, Via Cherasco 15, 10126, Turin, Italy. ^[2] Department of Neurosurgery, Cancer Institute, Rome, Italy. ^[3] Department of Medical Oncology, Regional Hospital, Bolzano, Italy. ^[4] Department of Neurosurgery, Regional Hospital, Milan, Italy. ^[5] Department of Medical Oncology, Regional Hospital, Cesena, Italy. ^[6] Department of Neurosurgery, University of Milan, Milan, Italy. ^[7] Unit of Cancer Epidemiology (CPO Piemonte), University of Turin, Turin, Italy. ^[8] Department of Biomedical Sciences, University and City of Health and Science Hospital, Turin, Italy. ^[9]

关键词 Grade II gliomas Oligodendrogliomas IDH-mutant and 1p/19q codeleted Response Survival Temozolomide WHO 2016